Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

The Effect of Gefapixant, a P2X3 antagonist, on Cough Reflex Sensitivity: A randomised placebo-controlled study.

Morice AH, Kitt MM, Ford AP, Tershakovec AM, Wu WC, Brindle K, Thompson R, Thackray-Nocera S, Wright C.

Eur Respir J. 2019 Apr 25. pii: 1900439. doi: 10.1183/13993003.00439-2019. [Epub ahead of print]

PMID:
31023843
2.

Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.

Richards D, Gever JR, Ford AP, Fountain SJ.

Br J Pharmacol. 2019 Jul;176(13):2279-2291. doi: 10.1111/bph.14677. Epub 2019 May 11.

PMID:
30927255
3.

Purinergic receptors in the carotid body as a new drug target for controlling hypertension.

Pijacka W, Moraes DJ, Ratcliffe LE, Nightingale AK, Hart EC, da Silva MP, Machado BH, McBryde FD, Abdala AP, Ford AP, Paton JF.

Nat Med. 2016 Oct;22(10):1151-1159. doi: 10.1038/nm.4173. Epub 2016 Sep 5.

4.

Hypertension: a problem of organ blood flow supply-demand mismatch.

Koeners MP, Lewis KE, Ford AP, Paton JF.

Future Cardiol. 2016 May;12(3):339-49. doi: 10.2217/fca.16.5. Epub 2016 Apr 19. Review.

5.

Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate.

Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA, Dubuis E, Ching YM, Ford AP, Shala F, Miralpeix M, Tarrason G, Smith JA, Belvisi MG.

J Allergy Clin Immunol. 2016 Jul;138(1):249-261.e12. doi: 10.1016/j.jaci.2015.10.044. Epub 2016 Jan 11.

6.

P2X3 receptor antagonist in chronic cough--Authors' reply.

Smith JA, Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP.

Lancet. 2015 Jul 18;386(9990):244-5. doi: 10.1016/S0140-6736(15)61275-2. No abstract available.

PMID:
26194520
7.

P2X3 receptors and sensitization of autonomic reflexes.

Ford AP, Undem BJ, Birder LA, Grundy D, Pijacka W, Paton JF.

Auton Neurosci. 2015 Sep;191:16-24. doi: 10.1016/j.autneu.2015.04.005. Epub 2015 Apr 25. Review.

PMID:
25956567
8.

Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway.

Copik AJ, Baldys A, Nguyen K, Sahdeo S, Ho H, Kosaka A, Dietrich PJ, Fitch B, Raymond JR, Ford AP, Button D, Milla ME.

PLoS One. 2015 Jan 21;10(1):e0115701. doi: 10.1371/journal.pone.0115701. eCollection 2015.

9.

Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice.

Vandenbeuch A, Larson ED, Anderson CB, Smith SA, Ford AP, Finger TE, Kinnamon SC.

J Physiol. 2015 Mar 1;593(5):1113-25. doi: 10.1113/jphysiol.2014.281014. Epub 2015 Jan 20.

10.

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA.

Lancet. 2015 Mar 28;385(9974):1198-205. doi: 10.1016/S0140-6736(14)61255-1. Epub 2014 Nov 25.

PMID:
25467586
11.

Inhibition of urothelial P2X3 receptors prevents desensitization of purinergic detrusor contractions in the rat bladder.

Ferguson AC, Sutton BW, Boone TB, Ford AP, Munoz A.

BJU Int. 2015 Aug;116(2):293-301. doi: 10.1111/bju.13003. Epub 2015 Mar 25.

12.

Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers.

Ye Y, Ono K, Bernabé DG, Viet CT, Pickering V, Dolan JC, Hardt M, Ford AP, Schmidt BL.

Acta Neuropathol Commun. 2014 Jun 5;2:62. doi: 10.1186/2051-5960-2-62.

13.

The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.

Ford AP, Undem BJ.

Front Cell Neurosci. 2013 Dec 19;7:267. doi: 10.3389/fncel.2013.00267. Review.

14.

A role for ATP in bronchoconstriction-induced activation of guinea pig vagal intrapulmonary C-fibres.

Weigand LA, Ford AP, Undem BJ.

J Physiol. 2012 Aug 15;590(16):4109-20. doi: 10.1113/jphysiol.2012.233460. Epub 2012 Jun 11.

15.

Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors.

Munoz A, Somogyi GT, Boone TB, Ford AP, Smith CP.

BJU Int. 2012 Oct;110(8 Pt B):E409-14. doi: 10.1111/j.1464-410X.2012.11189.x. Epub 2012 Apr 30.

16.

P2X3 antagonists: novel therapeutics for afferent sensitization and chronic pain.

Ford AP.

Pain Manag. 2012 May;2(3):267-77. doi: 10.2217/pmt.12.16.

PMID:
24654669
17.

In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.

Ford AP.

Purinergic Signal. 2012 Feb;8(Suppl 1):3-26. doi: 10.1007/s11302-011-9271-6. Epub 2011 Nov 18.

18.

Networks and the epidemiology of infectious disease.

Danon L, Ford AP, House T, Jewell CP, Keeling MJ, Roberts GO, Ross JV, Vernon MC.

Interdiscip Perspect Infect Dis. 2011;2011:284909. doi: 10.1155/2011/284909. Epub 2011 Mar 16.

19.

ATP and P2X purinoceptors in urinary tract disorders.

Ford AP, Cockayne DA.

Handb Exp Pharmacol. 2011;(202):485-526. doi: 10.1007/978-3-642-16499-6_22. Review.

PMID:
21290240
20.

Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats.

Kaan TK, Yip PK, Patel S, Davies M, Marchand F, Cockayne DA, Nunn PA, Dickenson AH, Ford AP, Zhong Y, Malcangio M, McMahon SB.

Brain. 2010 Sep;133(9):2549-64. doi: 10.1093/brain/awq194.

PMID:
20802203
21.

AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.

Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, Milla ME, Burnstock G, Ford AP.

Br J Pharmacol. 2010 Jul;160(6):1387-98. doi: 10.1111/j.1476-5381.2010.00796.x.

22.

Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord.

Kaan TK, Yip PK, Grist J, Cefalu JS, Nunn PA, Ford AP, Zhong Y, McMahon SB.

J Neurosci. 2010 Mar 24;30(12):4503-7. doi: 10.1523/JNEUROSCI.6132-09.2010.

23.

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Brotherton-Pleiss CE, Dillon MP, Ford AP, Gever JR, Carter DS, Gleason SK, Lin CJ, Moore AG, Thompson AW, Villa M, Zhai Y.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1031-6. doi: 10.1016/j.bmcl.2009.12.044. Epub 2009 Dec 16.

PMID:
20045645
24.

Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function.

Schnegelsberg B, Sun TT, Cain G, Bhattacharya A, Nunn PA, Ford AP, Vizzard MA, Cockayne DA.

Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R534-47. doi: 10.1152/ajpregu.00367.2009. Epub 2009 Dec 23. Erratum in: Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1447.

25.

Selective pharmacological blockade of the TRPV1 receptor suppresses sensory reflexes of the rodent bladder.

Cefalu JS, Guillon MA, Burbach LR, Zhu QM, Hu DQ, Ho MJ, Ford AP, Nunn PA, Cockayne DA.

J Urol. 2009 Aug;182(2):776-85. doi: 10.1016/j.juro.2009.03.085. Epub 2009 Jun 18.

PMID:
19539322
26.

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Carter DS, Alam M, Cai H, Dillon MP, Ford AP, Gever JR, Jahangir A, Lin C, Moore AG, Wagner PJ, Zhai Y.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1628-31. doi: 10.1016/j.bmcl.2009.02.003. Epub 2009 Feb 7.

PMID:
19231180
27.

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Jahangir A, Alam M, Carter DS, Dillon MP, Bois DJ, Ford AP, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5. doi: 10.1016/j.bmcl.2009.01.097. Epub 2009 Feb 4.

PMID:
19231178
28.

Facilitatory interplay in alpha 1a and beta 2 adrenoceptor function reveals a non-Gq signaling mode: implications for diversification of intracellular signal transduction.

Copik AJ, Ma C, Kosaka A, Sahdeo S, Trane A, Ho H, Dietrich PS, Yu H, Ford AP, Button D, Milla ME.

Mol Pharmacol. 2009 Mar;75(3):713-28. doi: 10.1124/mol.108.050765. Epub 2008 Dec 24.

PMID:
19109357
29.

The role of metabotropic glutamate receptor mGlu5 in control of micturition and bladder nociception.

Hu Y, Dong L, Sun B, Guillon MA, Burbach LR, Nunn PA, Liu X, Vilenski O, Ford AP, Zhong Y, Rong W.

Neurosci Lett. 2009 Jan 23;450(1):12-7. doi: 10.1016/j.neulet.2008.11.026. Epub 2008 Nov 14.

PMID:
19027050
30.

Expression and function of rat urothelial P2Y receptors.

Chopra B, Gever J, Barrick SR, Hanna-Mitchell AT, Beckel JM, Ford AP, Birder LA.

Am J Physiol Renal Physiol. 2008 Apr;294(4):F821-9. doi: 10.1152/ajprenal.00321.2006. Epub 2008 Jan 23.

31.

Effects of the selective prostacyclin receptor antagonist RO3244019 on the micturition reflex in rats.

Cefalu JS, Zhu QM, Eggers AC, Kaan TK, Ho MJ, Jett MF, Cockayne DA, Ford AP, Nunn PA.

J Urol. 2007 Dec;178(6):2683-8. Epub 2007 Oct 22.

PMID:
17945281
32.

Abnormalities in neuromuscular junction structure and skeletal muscle function in mice lacking the P2X2 nucleotide receptor.

Ryten M, Koshi R, Knight GE, Turmaine M, Dunn P, Cockayne DA, Ford AP, Burnstock G.

Neuroscience. 2007 Sep 7;148(3):700-11. Epub 2007 Jul 17.

PMID:
17706883
33.

Pharmacology of P2X channels.

Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP.

Pflugers Arch. 2006 Aug;452(5):513-37. Epub 2006 Apr 29. Review.

PMID:
16649055
34.

Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

Ford AP, Gever JR, Nunn PA, Zhong Y, Cefalu JS, Dillon MP, Cockayne DA.

Br J Pharmacol. 2006 Feb;147 Suppl 2:S132-43. Review.

35.

RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.

Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O'Yang C, Smith S, Srinivasan D, Ford AP, Jett MF.

Br J Pharmacol. 2006 Feb;147(3):335-45.

36.

Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.

Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P.

J Urol. 2005 Sep;174(3):977-82; discussion 982-3.

PMID:
16094018
37.

P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP.

Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, Ruan HZ, Ma B, Yip P, Nunn P, McMahon SB, Burnstock G, Ford AP.

J Physiol. 2005 Sep 1;567(Pt 2):621-39. Epub 2005 Jun 16.

38.

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.

Jaime-Figueroa S, Greenhouse R, Padilla F, Dillon MP, Gever JR, Ford AP.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3292-5.

PMID:
15927468
39.

Antagonism of ATP responses at P2X receptor subtypes by the pH indicator dye, Phenol red.

King BF, Liu M, Townsend-Nicholson A, Pfister J, Padilla F, Ford AP, Gever JR, Oglesby IB, Schorge S, Burnstock G.

Br J Pharmacol. 2005 Jun;145(3):313-22.

40.

Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification.

Clark RD, Jahangir A, Alam M, Rocha C, Lin L, Bjorner B, Nguyen K, Grady C, Williams TJ, Stepan G, Tang HM, Ford AP.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1697-700.

PMID:
15745824
41.

Effect of neurokinins on canine prostate cell physiology.

Walden PD, Marinese D, Srinivasan D, Tzoumaka E, Syyong HT, Ford AP, Bhattacharya A.

Prostate. 2005 Jun 1;63(4):358-68.

PMID:
15611996
42.

Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium.

Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, Ford AP, de Groat WC, Birder LA.

J Physiol. 2005 Feb 1;562(Pt 3):859-71. Epub 2004 Dec 2.

43.

Pharmacological and functional characterization of bradykinin B2 receptor in human prostate.

Srinivasan D, Kosaka AH, Daniels DV, Ford AP, Bhattacharya A.

Eur J Pharmacol. 2004 Nov 19;504(3):155-67.

PMID:
15541417
44.

Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis.

Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo JR, Ford AP, de Groat WC, Burnstock G.

Am J Physiol Renal Physiol. 2004 Nov;287(5):F1084-91. Epub 2004 Jul 13.

45.

P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin.

Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P.

Eur Urol. 2004 Aug;46(2):247-53.

PMID:
15245821
46.

Uropathic observations in mice expressing a constitutively active point mutation in the 5-HT3A receptor subunit.

Bhattacharya A, Dang H, Zhu QM, Schnegelsberg B, Rozengurt N, Cain G, Prantil R, Vorp DA, Guy N, Julius D, Ford AP, Lester HA, Cockayne DA.

J Neurosci. 2004 Jun 16;24(24):5537-48.

47.

Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate.

Srinivasan D, Burbach LR, Daniels DV, Ford AP, Bhattacharya A.

Br J Pharmacol. 2004 May;142(2):297-304.

48.

Identification of P2X receptors in cultured mouse and rat parasympathetic otic ganglion neurones including P2X knockout studies.

Ma B, Ruan HZ, Cockayne DA, Ford AP, Burnstock G, Dunn PM.

Neuropharmacology. 2004 Jun;46(7):1039-48.

PMID:
15081800
49.

Endothelial nitric oxide synthase expression in neurogenic urinary bladders treated with intravesical resiniferatoxin.

Apostolidis AN, Yiangou Y, Brady CM, Ford AP, Baecker PA, Jacques TS, Freeman A, Fowler CJ, Anand P.

BJU Int. 2004 Feb;93(3):336-40.

PMID:
14764132
50.

Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence.

Blue DR, Daniels DV, Gever JR, Jett MF, O'Yang C, Tang HM, Williams TJ, Ford AP.

BJU Int. 2004 Jan;93(1):162-70.

PMID:
14678390

Supplemental Content

Support Center